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CASE REPORTDevelopment of a reticular rash in a febrile woman:
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ngioimmunoblastic T-cell lymphoma (AITL)
is a peripheral T-cell lymphoma with a poor
prognosis in which 50% of patients present
with a rash.1,2 Although AITL’s cutaneous presenta-
tion is nonspecific, to our knowledge, a reticular rash
is not described in published literature.3 Herein, we
report a patient who presented with a generalized,
netlike rash, confirmed to be AITL upon histologic
analysis of a skin biopsy specimen.
CASE REPORT
A 59-year-old woman presented with a week-long
history of progressive, pruritic, pink, and lacy patches
on her trunk and extremities. Upon closer inspection,
physical examination revealed generalized erythem-
atous papules, macules, and patches in a netlike,
reticular pattern on her chest, abdomen, back, and
bilateral upper and lower extremities (Fig 1). Lesions
exhibited blanching with pressure but no scaling.
Mucosal surfaces were spared. Other concerns for
this patient included fever, abdominal pain, shortness
of breath, and hypotension. Laboratory values were
notable for elevated lactate dehydrogenase, elevated
white blood cell count, anemia, hyperbilirubinemia,
and hypofibrinogenemia. In addition, computed to-
mography imaging demonstrated worsening cervi-
cal, axillary, mediastinal, hilar, retroperitoneal, and
inguinal lymphadenopathy. The patient had recently
been admitted for recurrent pericardial effusions and
pneumonia, but no antibiotics had been introduced
within 2 weeks.
Biopsy specimen from the center of a lesion
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ountsinai.org.lymphocytic infiltrates, showing a pronounced an-
giocentric pattern and syringocentricity (Fig 2, A).
Small to medium vascular structures were involved
and were effaced by the infiltrate (Fig 2, B). Atypical
lymphocytes lined the dermoepidermal junction and
exhibited epidermotropism in a mycosis fungoides-
like pattern. With further immunohistology staining,
the infiltrate was found to be overwhelmingly
reactive for CD4, CD2, CD3, CD5, and CD7, focally
reactive for CD8, and rarely positive for CD20. CD34
revealed effaced vessels within the dense lymphoid
infiltrate. Ultimately, a diagnosis of AITL was
confirmed on skin and node biopsy specimens.
The patient’s coursewas complicated by recurrent
pericardial effusions and multiple admissions for
fever, attributed to both disease progress and
pneumonia. The patient was treated with chemo-
therapy, including cyclophosphamide, doxorubicin,
etoposide, vincristine, prednisone; ifosfamide,
carboplatin, and etoposide; gemcitabine, dexameth-
asone, and cisplatin; brentuximab; and romidepsin.
Weeks later, the patient developed sepsis secondary
to Clostridium difficile infection. After worsening
hypotension and subsequent cardiopulmonary
arrest, she died.
DISCUSSION
AITL is an uncommon systemic lymphoprolifer-
ative disorder that comprises 18% of all peripheral T-
cell lymphomas, with a mean onset age of 65 years.1
Diagnosis is often preceded by allergic reaction,
infection, or drug exposure with antibiotics being the
most commonly associated drug. It is proposed thatJAAD Case Reports 2015;1:160-2.
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Fig 1. Angioimmunoblastic T-cell lymphoma: clinical im-
age of generalized, pink, and lacy patches on bilateral
upper extremities.
Fig 2. Angioimmunoblastic T-cell lymphoma. A, Skin
biopsy specimen showed dense lymphoid infiltrates in
the papillary and reticular dermis. B, Histology revealed
dense, small to medium lymphocytes surrounding vessels,
effacing vascular structures. (A and B, Hematoxylin-eosin
stain; original magnifications: A, 340; B, 3200.)
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immune dysregulation and therefore disease.
However, the exact origin is unknown.2
In order of decreasing frequency, clinical features
consist of generalized lymphadenopathy, constitu-
tional symptoms (fever,weight loss, andnight sweats),
hepatosplenomegaly, cutaneous involvement,pleural
effusion, edema, and ascites.2 Cutaneous findings of
AITL arenonspecific, althoughusually associatedwith
pruritus, a symptom our patient endorsed. Most
commonly,morbilliformeruptions are reported; how-
ever, purpura, urticaria, nodules, and petechiae havealso been described.3 Because of these nonspecific
findings, AITL poses a diagnostic challenge when
presenting as a rash but should be considered when
systemic symptoms suggest AITL.4
Laboratory abnormalities associated with AITL
include anemia, hypergammaglobulinemia, elevated
serum lactate dehydrogenase, and elevated erythro-
cyte sedimentation rate.3 Although features can be
subtle or variable, histopathology is particularly
essential for diagnosis. The most common finding is
a superficial perivascular infiltrate with or without
atypical lymphocytes. Specimens also usually
demonstrate increased vascularity. Classically,
perivascular infiltrates of neoplastic T cells express
CD2, CD3, CD4, CD5, and occasionally CD8, as seen
in our patient.4 Although skin biopsy specimens of
cutaneous T-cell lymphomas, such as mycosis
fungoides, feature similar lymphoid infiltrates,
systemic symptoms in cutaneous T-cell lymphoma
typically manifest long after advanced skin involve-
ment; in addition, cutaneous T-cell lymphoma can
reliably be diagnosed by TCR gene arrangement
studies via polymerase chain reaction.5 If diagnosis
is still unclear, stains for follicular T-helper cell
markers (CD10, CXCL13, PD-1, BCL-6, and CD40-L)
are more specific to AITL.4,6 Node biopsy specimen
further confirms the diagnosis.
The differential diagnosis for reticular eruptions
includes livedo reticularis and drug hypersensitivity.
Triggered by decreased vascular flow or vessel-wall
pathology, causes of livedo reticularis include
connective tissue diseases, hypercoagulable states
(eg, antiphospholipid syndrome), and vasculitides
(eg, polyarteritis nodosa, cryoglobulinemia). These
diagnoses can be differentiated from AITL via clinical
symptoms, skin biopsy specimen, and investigative
laboratory tests (eg, coagulation studies, lupus
anticoagulant, antiphospholipid antibodies, cryoglo-
bulins, antinuclear antibodies).7 Rarely, drugs can
also cause a reticular eruption. Amantadine is a
particular drug characterized in this context, but
affected patients report recent introduction of
amantadine and no other systemic side effects.8 Our
patient did not report a history or symptoms to
suggest any of these other diagnoses.
Unfortunately, therapeutic options for AITL have
been disappointing without improved survival rates
during the last 20 years. In fact, survival probability is
still less than 50% at 2 years after diagnosis.9
Anthracycline-based therapy, including cyclophos-
phamide, doxorubicin, vincristine, and prednisone,
is considered first-line, but early relapse and
infectious complications are common.10 Newer
treatments have been implemented but with mixed
success. These therapies include (1) rituximab, an
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genic agents, such as cyclosporine, interferon, bev-
acizumab, and thalidomide; (3) romidepsin, which
leads to growth arrest and apoptosis; and (4)
alemtuzumab, which targets CD52 on B and T
cells.2,10
Rapid diagnosis and treatment of AITL is impera-
tive. Because cutaneous presentations of AITL are
variable, we suggest that clinicians consider AITL if a
patient presentswith a generalized, pruritic rash in the
context of lymphadenopathy, fever, pleural effusions,
and recent infections. Albeit rare, a reticular rash is a
plausible cutaneous presentation of AITL. If con-
cerned for AITL, clinicians should obtain a skin biopsy
specimen and request immunohistological staining.
We are indebted to Dr Robert Phelps and the
Dermatopathology Department at Mount Sinai Medical
Center for assistance in obtaining and interpreting histo-
pathology images. We also thank the patient’s family for
providing permission to share the patient’s information.
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